1
|
Schäker‐Hübner L, Haschemi R, Büch T, Kraft FB, Brumme B, Schöler A, Jenke R, Meiler J, Aigner A, Bendas G, Hansen FK. Front Cover: Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors (ChemMedChem 9/2022). ChemMedChem 2022. [DOI: 10.1002/cmdc.202200210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Linda Schäker‐Hübner
- Institut für Wirkstoffentwicklung Medizinische Fakultät Universität Leipzig Brüderstraße 34 04103 Leipzig Germany
- Abteilung für Pharmazeutische und Zellbiologische Chemie Pharmazeutisches Institut Universität Bonn An der Immenburg 4 53121 Bonn Germany
| | - Reza Haschemi
- Abteilung für Pharmazeutische und Zellbiologische Chemie Pharmazeutisches Institut Universität Bonn An der Immenburg 4 53121 Bonn Germany
| | - Thomas Büch
- Rudolf-Boehm-Institut für Pharmakologie und Toxikologie, Klinische Pharmakologie Medizinische Fakultät Universität Leipzig Härtelstraße 16–18 04107 Leipzig Germany
| | - Fabian B. Kraft
- Abteilung für Pharmazeutische und Zellbiologische Chemie Pharmazeutisches Institut Universität Bonn An der Immenburg 4 53121 Bonn Germany
| | - Birke Brumme
- Institut für Wirkstoffentwicklung Medizinische Fakultät Universität Leipzig Brüderstraße 34 04103 Leipzig Germany
| | - Andrea Schöler
- Institut für Wirkstoffentwicklung Medizinische Fakultät Universität Leipzig Brüderstraße 34 04103 Leipzig Germany
| | - Robert Jenke
- Rudolf-Boehm-Institut für Pharmakologie und Toxikologie, Klinische Pharmakologie Medizinische Fakultät Universität Leipzig Härtelstraße 16–18 04107 Leipzig Germany
- University Cancer Center Leipzig (UCCL) Universitätsklinikum Leipzig Liebigstraße 22, Haus 7 04103 Leipzig Germany
| | - Jens Meiler
- Institut für Wirkstoffentwicklung Medizinische Fakultät Universität Leipzig Brüderstraße 34 04103 Leipzig Germany
| | - Achim Aigner
- Rudolf-Boehm-Institut für Pharmakologie und Toxikologie, Klinische Pharmakologie Medizinische Fakultät Universität Leipzig Härtelstraße 16–18 04107 Leipzig Germany
| | - Gerd Bendas
- Abteilung für Pharmazeutische und Zellbiologische Chemie Pharmazeutisches Institut Universität Bonn An der Immenburg 4 53121 Bonn Germany
| | - Finn K. Hansen
- Abteilung für Pharmazeutische und Zellbiologische Chemie Pharmazeutisches Institut Universität Bonn An der Immenburg 4 53121 Bonn Germany
| |
Collapse
|
2
|
Schäker-Hübner L, Haschemi R, Büch T, Kraft FB, Brumme B, Schöler A, Jenke R, Meiler J, Aigner A, Bendas G, Hansen FK. Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors. ChemMedChem 2022; 17:e202100755. [PMID: 35073610 PMCID: PMC9303312 DOI: 10.1002/cmdc.202100755] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Indexed: 11/08/2022]
Abstract
Herein we report the structure‐activity and structure‐physicochemical property relationships of a series of class I selective ortho‐aminoanilides targeting the “foot‐pocket” in HDAC1&2. To balance the structural benefits and the physicochemical disadvantages of these substances, we started with a set of HDACi related to tacedinaline (CI‐994) and evaluated their solubility, lipophilicity (log D7.4) and inhibition of selected HDAC isoforms. Subsequently, we selected the most promising “capless” HDACi and transferred its ZBG to our previously published scaffold featuring a peptoid‐based cap group. The resulting hit compound 10 c (LSH‐A54) showed favorable physicochemical properties and is a potent, selective HDAC1/2 inhibitor. The following evaluation of its slow binding properties revealed that LSH‐A54 binds tightly to HDAC1 in an induced‐fit mechanism. The potent HDAC1/2 inhibitory properties were reflected by attenuated cell migration in a modified wound healing assay and reduced cell viability in a clonogenic survival assay in selected breast cancer cell lines.
Collapse
Affiliation(s)
| | - Reza Haschemi
- Rheinische Friedrich-Wilhelms-Universität Bonn: Rheinische Friedrich-Wilhelms-Universitat Bonn Pharmaceutical and Cell Biological Chemistry GERMANY
| | - Thomas Büch
- Leipzig University: Universitat Leipzig Rudolf-Böhm-Institut GERMANY
| | - Fabian B Kraft
- Rheinische Friedrich-Wilhelms-Universitat Bonn Pharmaceutical and Cell Biological Chemistry GERMANY
| | - Birke Brumme
- Leipzig University: Universitat Leipzig Institute for Drug Discovery GERMANY
| | - Andrea Schöler
- Leipzig University: Universitat Leipzig Institute for Drug Discovery GERMANY
| | - Robert Jenke
- Leipzig University: Universitat Leipzig Rudlof-Böhm-Institut GERMANY
| | - Jens Meiler
- Leipzig University: Universitat Leipzig Institute for Drug Discovery GERMANY
| | - Achim Aigner
- Leipzig University: Universitat Leipzig Rudolf-Böhm-Institut GERMANY
| | - Gerd Bendas
- Rheinische Friedrich-Wilhelms-Universität Bonn: Rheinische Friedrich-Wilhelms-Universitat Bonn Pharmaceutical and Cell Biological Chemistry GERMANY
| | - Finn Kristian Hansen
- Rheinische Friedrich-Wilhelms-Universitat Bonn Pharmaceutical Institute An der Immenburg 4 53121 Bonn GERMANY
| |
Collapse
|
3
|
Haschemi R, Gockel LM, Bendas G, Schlesinger M. A Combined Activity of Thrombin and P-Selectin Is Essential for Platelet Activation by Pancreatic Cancer Cells. Int J Mol Sci 2021; 22:3323. [PMID: 33805059 PMCID: PMC8037188 DOI: 10.3390/ijms22073323] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2020] [Revised: 03/15/2021] [Accepted: 03/21/2021] [Indexed: 01/01/2023] Open
Abstract
Pancreatic cancer patients have an elevated risk of suffering from venous thrombosis. Among several risk factors that contribute to hypercoagulability of this malignancy, platelets possess a key role in the initiation of clot formation. Although single mechanisms of platelet activation are well-known in principle, combinations thereof and their potential synergy to mediate platelet activation is, in the case of pancreatic cancer, far from being clear. Applying an inhibitor screening approach using light transmission aggregometry, dense granule release, and thrombin formation assays, we provide evidence that a combination of tissue factor-induced thrombin formation by cancer cells and their platelet P-selectin binding is responsible for AsPC-1 and Capan-2 pancreatic cancer cell-mediated platelet activation. While the blockade of one of these pathways leads to a pronounced inhibition of platelet aggregation and dense granule release, the simultaneous blockade of both pathways is inevitable to prevent platelet aggregation completely and minimize ATP release. In contrast, MIA PaCa-2 pancreatic cancer cells express reduced levels of tissue factor and P-selectin ligands and thus turn out to be poor platelet activators. Consequently, a simultaneous blockade of thrombin and P-selectin binding seems to be a powerful approach, as mediated by heparin to crucially reduce the hypercoagulable state of pancreatic cancer patients.
Collapse
Affiliation(s)
| | | | | | - Martin Schlesinger
- Pharmaceutical Institute, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany; (R.H.); (L.M.G.); (G.B.)
| |
Collapse
|
4
|
Steinebach C, Ng YLD, Sosič I, Lee CS, Chen S, Lindner S, Vu LP, Bricelj A, Haschemi R, Monschke M, Steinwarz E, Wagner KG, Bendas G, Luo J, Gütschow M, Krönke J. Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders. Chem Sci 2020; 11:3474-3486. [PMID: 33133483 PMCID: PMC7552917 DOI: 10.1039/d0sc00167h] [Citation(s) in RCA: 72] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2020] [Accepted: 02/28/2020] [Indexed: 12/18/2022] Open
Abstract
Cyclin-dependent kinase 6 (CDK6) is an important regulator of the cell cycle. Together with CDK4, it phosphorylates and inactivates retinoblastoma (Rb) protein.
Cyclin-dependent kinase 6 (CDK6) is an important regulator of the cell cycle. Together with CDK4, it phosphorylates and inactivates retinoblastoma (Rb) protein. In tumour cells, CDK6 is frequently upregulated and CDK4/6 kinase inhibitors like palbociclib possess high activity in breast cancer and other malignancies. Besides its crucial catalytic function, kinase-independent roles of CDK6 have been described. Therefore, targeted degradation of CDK6 may be advantageous over kinase inhibition. Proteolysis targeting chimeras (PROTACs) structurally based on the cereblon (CRBN) ligand thalidomide have recently been described to degrade the targets CDK4/6. However, CRBN-based PROTACs have several limitations including the remaining activity of immunomodulatory drugs (IMiDs) on Ikaros transcription factors as well as CRBN inactivation as a resistance mechanism in cancer. Here, we systematically explored the chemical space of CDK4/6 PROTACs by addressing different E3 ligases and connecting their respective small-molecule binders via various linkers to palbociclib. The spectrum of CDK6-specific PROTACs was extended to von Hippel Lindau (VHL) and cellular inhibitor of apoptosis protein 1 (cIAP1) that are essential for most cancer cells and therefore less likely to be inactivated. Our VHL-based PROTAC series included compounds that were either specific for CDK6 or exhibited dual activity against CDK4 and CDK6. IAP-based PROTACs caused a combined degradation of CDK4/6 and IAPs resulting in synergistic effects on cancer cell growth. Our new degraders showed potent and long-lasting degrading activity in human and mouse cells and inhibited proliferation of several leukemia, myeloma and breast cancer cell lines. In conclusion, we show that VHL- and IAP-based PROTACs are an attractive approach for targeted degradation of CDK4/6 in cancer.
Collapse
Affiliation(s)
- Christian Steinebach
- Pharmaceutical Institute , Department of Pharmaceutical & Medicinal Chemistry , University of Bonn , An der Immenburg 4 , 53121 Bonn , Germany .
| | - Yuen Lam Dora Ng
- Department of Internal Medicine III , University Hospital Ulm , Albert-Einstein-Allee 23 , 89081 Ulm , Germany .
| | - Izidor Sosič
- Faculty of Pharmacy , University of Ljubljana , Aškerčeva cesta 7 , 1000 Ljubljana , Slovenia
| | - Chih-Shia Lee
- Laboratory of Cancer Biology and Genetics , Center for Cancer Research , National Cancer Institute , Bethesda , MD 20892 , USA
| | - Sirui Chen
- Department of Internal Medicine III , University Hospital Ulm , Albert-Einstein-Allee 23 , 89081 Ulm , Germany .
| | - Stefanie Lindner
- Department of Internal Medicine III , University Hospital Ulm , Albert-Einstein-Allee 23 , 89081 Ulm , Germany .
| | - Lan Phuong Vu
- Pharmaceutical Institute , Department of Pharmaceutical & Medicinal Chemistry , University of Bonn , An der Immenburg 4 , 53121 Bonn , Germany .
| | - Aleša Bricelj
- Faculty of Pharmacy , University of Ljubljana , Aškerčeva cesta 7 , 1000 Ljubljana , Slovenia
| | - Reza Haschemi
- Pharmaceutical Institute , Department of Pharmaceutical & Cell Biological Chemistry , University of Bonn , An der Immenburg 4 , 53121 Bonn , Germany
| | - Marius Monschke
- Pharmaceutical Institute , Pharmaceutical Technology , University of Bonn , Gerhard-Domagk-Straße 3 , 53121 Bonn , Germany
| | - Elisabeth Steinwarz
- Pharmaceutical Institute , Department of Pharmaceutical & Cell Biological Chemistry , University of Bonn , An der Immenburg 4 , 53121 Bonn , Germany
| | - Karl G Wagner
- Pharmaceutical Institute , Pharmaceutical Technology , University of Bonn , Gerhard-Domagk-Straße 3 , 53121 Bonn , Germany
| | - Gerd Bendas
- Pharmaceutical Institute , Department of Pharmaceutical & Cell Biological Chemistry , University of Bonn , An der Immenburg 4 , 53121 Bonn , Germany
| | - Ji Luo
- Laboratory of Cancer Biology and Genetics , Center for Cancer Research , National Cancer Institute , Bethesda , MD 20892 , USA
| | - Michael Gütschow
- Pharmaceutical Institute , Department of Pharmaceutical & Medicinal Chemistry , University of Bonn , An der Immenburg 4 , 53121 Bonn , Germany .
| | - Jan Krönke
- Department of Internal Medicine III , University Hospital Ulm , Albert-Einstein-Allee 23 , 89081 Ulm , Germany .
| |
Collapse
|
5
|
Ponert JM, Schwarz S, Haschemi R, Müller J, Pötzsch B, Bendas G, Schlesinger M. The mechanisms how heparin affects the tumor cell induced VEGF and chemokine release from platelets to attenuate the early metastatic niche formation. PLoS One 2018; 13:e0191303. [PMID: 29346400 PMCID: PMC5773218 DOI: 10.1371/journal.pone.0191303] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2017] [Accepted: 01/01/2018] [Indexed: 11/18/2022] Open
Abstract
Metastasis is responsible for the majority of cancer associated fatalities. Tumor cells leaving the primary tumor and entering the blood flow immediately interact with platelets. Activated platelets contribute in different ways to cancer cell survival and proliferation, e.g. in formation of the early metastatic niche by release of different growth factors and chemokines. Here we show that a direct interaction between platelets and MV3 melanoma or MCF7 breast cancer cells induces platelet activation and a VEGF release in citrated plasma that cannot be further elevated by the coagulation cascade and generated thrombin. In contrast, the release of platelet-derived chemokines CXCL5 and CXCL7 depends on both, a thrombin-mediated platelet activation and a direct interaction between tumor cells and platelets. Preincubation of platelets with therapeutic concentrations of unfractionated heparin reduces the tumor cell initiated VEGF release from platelets. In contrast, tumor cell induced CXCL5 and CXCL7 release from platelets was not impacted by heparin pretreatment in citrated plasma. In defibrinated, recalcified plasma, on the contrary, heparin is able to reduce CXCL5 and CXCL7 release from platelets by thrombin inhibition. Our data indicate that different chemokines and growth factors in diverse platelet granules are released in tightly regulated processes by various trigger mechanisms. We show for the first time that heparin is able to reduce the mediator release induced by different tumor cells both in a contact and coagulation dependent manner.
Collapse
Affiliation(s)
- Jan Moritz Ponert
- Department of Pharmacy, Rheinische Friedrich-Wilhelms-University Bonn, Bonn, Germany
| | - Svenja Schwarz
- Department of Pharmacy, Rheinische Friedrich-Wilhelms-University Bonn, Bonn, Germany
| | - Reza Haschemi
- Department of Pharmacy, Rheinische Friedrich-Wilhelms-University Bonn, Bonn, Germany
| | - Jens Müller
- Institute for Experimental Hematology and Transfusion Medicine, University of Bonn Medical Centre, Bonn, Germany
| | - Bernd Pötzsch
- Institute for Experimental Hematology and Transfusion Medicine, University of Bonn Medical Centre, Bonn, Germany
| | - Gerd Bendas
- Department of Pharmacy, Rheinische Friedrich-Wilhelms-University Bonn, Bonn, Germany
| | - Martin Schlesinger
- Department of Pharmacy, Rheinische Friedrich-Wilhelms-University Bonn, Bonn, Germany
- * E-mail:
| |
Collapse
|
6
|
Kugler A, Haschemi R, Zöller G, Gross AJ, Kallerhoff M, Ringert RH. In vitro investigations of new therapeutic agents on bladder tumor cell lines. Urol Res 1997; 25:247-50. [PMID: 9286032 DOI: 10.1007/bf00942093] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
In this study sensitivity of human transitional cancer cells to the anticancer agent paclitaxel, an antimicrotubular drug, and to gallium nitrate, a group IIIa metal, was compared to that of the standard MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) drugs. The reduction of cell proliferation was evaluated after 48 h of incubation of six different cell lines with each agent using the mean transit time (MTT) assay. We investigated both monolayers and spheroids. Paclitaxel showed significantly higher growth inhibitory effects on monolayers than vinblastine, both agents targeting the antimicrotubular apparatus. This could not be reproduced on spheroids, where a survival fraction of 50% was observed even at high concentrations (10 microM). High concentrations of gallium nitrate were needed to achieve sufficient toxicity. These concentrations are beyond the concentration achievable by systemic application. Our findings suggest that paclitaxel may be a clinically useful agent for systemic and intravesical use in bladder cancer.
Collapse
Affiliation(s)
- A Kugler
- Department of Urology, Georg-August University, Göttingen, Germany
| | | | | | | | | | | |
Collapse
|